K2M Group Holdings, Inc. of Leesburg, Virginia and LifeHealthcare Group Limited of Australia-New Zealand, after concluding a successful seven year partnership, have entered into a new five year supply agreement to distribute K2M’s spinal technologies. The partnership’s goal is to establish the number one spine market position in Australia and New Zealand.
K2M Partners With Aussie/Kiwi Firm
2 min read Premium comments
Secondary
K2M Group Holdings, Inc. is a producer of complex spine and minimally invasive solutions focused on achieving three-dimensional Total Body Balance. Since its inception, K2M has designed, and commercialized complex spine and minimally invasive spine technologies and techniques to treat the most complicated spinal pathologies. K2M has leveraged these core competencies into Balance ACS, a platform of products, services, and research to help surgeons achieve three-dimensional spinal balance across the axial, coronal and sagittal planes. The Balance ACS platform, in combination with the company’s leadership in the 3D-printing of spinal devices, enable K2M to compete.
LifeHealthcare Group Limited is an independent provider of healthcare solutions in Australia and New Zealand. The company works across specialized therapeutic channels bringing Australian and New Zealand healthcare professionals innovative medical devices.
Matt Muscio, LifeHealthcare’s CEO, stated, “I am very pleased to announce our new five-year contract with K2M through 2021. K2M is a globally recognized innovator in complex spine, having led the way in deformity and now minimally invasive and 3D-printed spine solutions. Through our partnership, we have delivered highly successful product initiatives and market leading education forums, such as Deformity Down Under. We look forward to working with Eric Major and the K2M team over the coming years to reach our shared aspiration of the number one market share position in the Australian and New Zealand spine market.”
K2M President and CEO Eric Major stated, “LifeHealthcare has been an important strategic partner of ours for many years and their established distribution presence and strong surgeon relationships have been instrumental in K2M’s strong market share growth in Australia and New Zealand. We are happy to announce our new agreement and look forward to offering innovative spinal technologies, such as our 3D-printed CASCADIA™ Lateral Interbody System, and our comprehensive Balance ACS™ platform focused on achieving three-dimensional spinal balance, to surgeons in this important international spine market.”
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.